{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:21:50Z","timestamp":1790713310779,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:00:00Z","timestamp":1490918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diabetes Mellitus is associated with severe cardiovascular disorders involving the renin-angiotensin system, mainly through activation of the angiotensin II type 1 receptor (AT1R). Although the type 2 receptor (AT2R) opposes the effects of AT1R, with vasodilator and anti-trophic properties, its role in diabetes is debatable. Thus we investigated AT2R-mediated dilatation in a model of type 1 diabetes induced by streptozotocin in 5-month-old male mice lacking AT2R (AT2R<jats:sup>\u2212\/y<\/jats:sup>). Glucose tolerance was reduced and markers of inflammation and oxidative stress (cyclooxygenase-2, gp91phox p22phox and p67phox) were increased in AT2R<jats:sup>\u2212\/y<\/jats:sup>mice compared to wild-type (WT) animals. Streptozotocin-induced hyperglycaemia was higher in AT2R<jats:sup>\u2212\/y<\/jats:sup>than in WT mice. Arterial gp91phox and MnSOD expression levels in addition to blood 8-isoprostane and creatinine were further increased in diabetic AT2R<jats:sup>\u2212\/y<\/jats:sup>mice compared to diabetic WT mice. AT2R-dependent dilatation in both isolated mesenteric resistance arteries and perfused kidneys was greater in diabetic mice than in non-diabetic animals. Thus, in type 1 diabetes, AT2R may reduce glycaemia and display anti-oxidant and\/or anti-inflammatory properties in association with greater vasodilatation in mesenteric arteries and in the renal vasculature, a major target of diabetes. Therefore AT2R might represent a new therapeutic target in diabetes.<\/jats:p>","DOI":"10.1038\/srep45625","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T11:23:37Z","timestamp":1490959417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Microvascular vasodilator properties of the angiotensin II type 2 receptor in a mouse model of type 1 diabetes"],"prefix":"10.1038","volume":"7","author":[{"given":"Marc-Antoine","family":"Begorre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Habchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Guihot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bourreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Vessieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Blondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Loufrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Chabbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Henrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Fassot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,31]]},"reference":[{"key":"BFsrep45625_CR1","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMoa022314","volume":"348","author":"DM Nathan","year":"2003","unstructured":"Nathan, D. M. et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348, 2294\u20132303, doi: 10.1056\/NEJMoa022314 (2003).","journal-title":"N Engl J Med"},{"key":"BFsrep45625_CR2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7861\/clinmedicine.10-5-495","volume":"10","author":"AW Roberts","year":"2010","unstructured":"Roberts, A. W. Cardiovascular risk and prevention in diabetes mellitus. Clinical medicine 10, 495\u2013499 (2010).","journal-title":"Clinical medicine"},{"key":"BFsrep45625_CR3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3810\/pgm.2009.03.1980","volume":"121","author":"JB McGill","year":"2009","unstructured":"McGill, J. B. Improving microvascular outcomes in patients with diabetes through management of hypertension. Postgrad Med 121, 89\u2013101 (2009).","journal-title":"Postgrad Med"},{"key":"BFsrep45625_CR4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.hjh.0000191244.91314.9d","volume":"24","author":"M Burnier","year":"2006","unstructured":"Burnier, M. & Zanchi, A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Journal of hypertension 24, 11\u201325 (2006).","journal-title":"Journal of hypertension"},{"key":"BFsrep45625_CR5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.clinthera.2007.09.019","volume":"29","author":"MR Weir","year":"2007","unstructured":"Weir, M. R. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29, 1803\u20131824 (2007).","journal-title":"Clin Ther"},{"key":"BFsrep45625_CR6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","volume":"52","author":"M de Gasparo","year":"2000","unstructured":"de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W. & Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52, 415\u2013472 (2000).","journal-title":"Pharmacol Rev"},{"key":"BFsrep45625_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/HYPERTENSIONAHA.106.085035","volume":"50","author":"F Pinaud","year":"2007","unstructured":"Pinaud, F. et al. Paradoxical role of angiotensin II type 2 receptors in resistance arteries of old rats. Hypertension 50, 96\u2013102 (2007).","journal-title":"Hypertension"},{"key":"BFsrep45625_CR8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bjp.0703371","volume":"130","author":"K Matrougui","year":"2000","unstructured":"Matrougui, K., Levy, B. I. & Henrion, D. Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats. British journal of pharmacology 130, 521\u2013526 (2000).","journal-title":"British journal of pharmacology"},{"key":"BFsrep45625_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1161\/01.HYP.24.3.317","volume":"24","author":"HY Qiu","year":"1994","unstructured":"Qiu, H. Y., Henrion, D. & Levy, B. I. Endogenous angiotensin II enhances phenylephrine-induced tone in hypertensive rats. Hypertension 24, 317\u2013321 (1994).","journal-title":"Hypertension"},{"key":"BFsrep45625_CR10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1210\/en.2013-1601","volume":"155","author":"C Shao","year":"2014","unstructured":"Shao, C., Yu, L. & Gao, L. Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection. Endocrinology 155, 793\u2013804, (2014).","journal-title":"Endocrinology"},{"key":"BFsrep45625_CR11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/FJC.0000000000000207","volume":"65","author":"LC Matavelli","year":"2015","unstructured":"Matavelli, L. C., Zatz, R. & Siragy, H. M. A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes. J Cardiovasc Pharmacol 65, 371\u2013376, (2015).","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFsrep45625_CR12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.numecd.2009.03.011","volume":"19","author":"D Rizzoni","year":"2009","unstructured":"Rizzoni, D. & Rosei, E. A. Small artery remodeling in diabetes mellitus. Nutrition, metabolism, and cardiovascular diseases: NMCD 19, 587\u2013592 (2009).","journal-title":"Nutrition, metabolism, and cardiovascular diseases: NMCD"},{"key":"BFsrep45625_CR13","doi-asserted-by":"crossref","first-page":"H1183","DOI":"10.1152\/ajpheart.00327.2012","volume":"303","author":"R Zhang","year":"2012","unstructured":"Zhang, R., Thor, D., Han, X., Anderson, L. & Rahimian, R. Sex differences in mesenteric endothelial function of streptozotocin-induced diabetic rats: a shift in the relative importance of EDRFs. Am J Physiol Heart Circ Physiol 303, H1183\u20131198 (2012).","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFsrep45625_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1113\/jphysiol.2006.126193","volume":"580","author":"PS Leung","year":"2007","unstructured":"Leung, P. S. The physiology of a local renin-angiotensin system in the pancreas. J Physiol 580, 31\u201337 (2007).","journal-title":"J Physiol"},{"key":"BFsrep45625_CR15","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/me.2004-0536","volume":"20","author":"L Hunyady","year":"2006","unstructured":"Hunyady, L. & Catt, K. J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20, 953\u2013970 (2006).","journal-title":"Mol Endocrinol"},{"key":"BFsrep45625_CR16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0165-6147(03)00233-5","volume":"24","author":"H Cai","year":"2003","unstructured":"Cai, H., Griendling, K. K. & Harrison, D. G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends in pharmacological sciences 24, 471\u2013478 (2003).","journal-title":"Trends in pharmacological sciences"},{"key":"BFsrep45625_CR17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.brainres.2008.03.020","volume":"1209","author":"DM Arrick","year":"2008","unstructured":"Arrick, D. M., Sharpe, G. M., Sun, H. & Mayhan, W. G. Losartan improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type 1 diabetic rats. Brain Res 1209, 128\u2013135 (2008).","journal-title":"Brain Res"},{"key":"BFsrep45625_CR18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/bph.13063","volume":"173","author":"AK Sampson","year":"2015","unstructured":"Sampson, A. K. et al. Compound 21 prevents endothelial inflammation and leukocyte adhesion in vitro and in vivo . British journal of pharmacology 173, 729\u201340 (2015).","journal-title":"British journal of pharmacology"},{"key":"BFsrep45625_CR19","doi-asserted-by":"crossref","first-page":"e113035","DOI":"10.1371\/journal.pone.0113035","volume":"9","author":"V Oliveira","year":"2014","unstructured":"Oliveira, V. et al. Influence of aerobic training on the reduced vasoconstriction to angiotensin II in rats exposed to intrauterine growth restriction: possible role of oxidative stress and AT2 receptor of angiotensin II. PloS one 9, e113035 (2014).","journal-title":"PloS one"},{"key":"BFsrep45625_CR20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5527\/wjn.v3.i3.64","volume":"3","author":"FM Ferrao","year":"2014","unstructured":"Ferrao, F. M., Lara, L. S. & Lowe, J. Renin-angiotensin system in the kidney: What is new? World journal of nephrology 3, 64\u201376 (2014).","journal-title":"World journal of nephrology"},{"key":"BFsrep45625_CR21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/FJC.0000000000000208","volume":"65","author":"LC Matavelli","year":"2015","unstructured":"Matavelli, L. C. & Siragy, H. M. AT2 receptor activities and pathophysiological implications. J Cardiovasc Pharmacol 65, 226\u2013232 (2015).","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFsrep45625_CR22","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1007\/s00125-010-1837-2","volume":"53","author":"KC Sourris","year":"2010","unstructured":"Sourris, K. C. et al. Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 53, 2442\u20132451 (2010).","journal-title":"Diabetologia"},{"key":"BFsrep45625_CR23","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.HYP.34.4.659","volume":"34","author":"K Matrougui","year":"1999","unstructured":"Matrougui, K., Loufrani, L., Heymes, C., Levy, B. I. & Henrion, D. Activation of AT(2) receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries. Hypertension 34, 659\u2013665 (1999).","journal-title":"Hypertension"},{"key":"BFsrep45625_CR24","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/01.CIR.0000156503.62815.48","volume":"111","author":"D You","year":"2005","unstructured":"You, D. et al. High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 111, 1006\u20131011 (2005).","journal-title":"Circulation"},{"key":"BFsrep45625_CR25","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/01.HYP.0000033224.99806.8A","volume":"40","author":"RE Widdop","year":"2002","unstructured":"Widdop, R. E., Matrougui, K., Levy, B. I. & Henrion, D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 40, 516\u2013520 (2002).","journal-title":"Hypertension"},{"key":"BFsrep45625_CR26","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1097\/01.hjh.0000251902.85675.7e","volume":"24","author":"C Savoia","year":"2006","unstructured":"Savoia, C. et al. Angiotensin II\/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. Journal of hypertension 24, 2417\u20132422 (2006).","journal-title":"Journal of hypertension"},{"key":"BFsrep45625_CR27","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1161\/01.CIR.0000128696.12245.57","volume":"109","author":"WW Batenburg","year":"2004","unstructured":"Batenburg, W. W. et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109, 2296\u20132301 (2004).","journal-title":"Circulation"},{"key":"BFsrep45625_CR28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1161\/01.HYP.0000253968.95136.b8","volume":"49","author":"C Savoia","year":"2007","unstructured":"Savoia, C., Touyz, R. M., Volpe, M. & Schiffrin, E. L. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49, 341\u2013346 (2007).","journal-title":"Hypertension"},{"key":"BFsrep45625_CR29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.109.140236","volume":"55","author":"K Retailleau","year":"2010","unstructured":"Retailleau, K. et al. Reactive oxygen species and cyclooxygenase 2-derived thromboxane A2 reduce angiotensin II type 2 receptor vasorelaxation in diabetic rat resistance arteries. Hypertension 55, 339\u2013344 (2010).","journal-title":"Hypertension"},{"key":"BFsrep45625_CR30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2010.11.004","volume":"17","author":"EJ Whalen","year":"2011","unstructured":"Whalen, E. J., Rajagopal, S. & Lefkowitz, R. J. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol Med 17, 126\u2013139 (2011).","journal-title":"Trends Mol Med"},{"key":"BFsrep45625_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.110.231308","volume":"109","author":"SM DeWire","year":"2011","unstructured":"DeWire, S. M. & Violin, J. D. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. Circ Res 109, 205\u2013216 (2011).","journal-title":"Circ Res"},{"key":"BFsrep45625_CR32","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.tcm.2013.01.002","volume":"23","author":"JD Violin","year":"2013","unstructured":"Violin, J. D., Soergel, D. G., Boerrigter, G., Burnett, J. C. Jr. & Lark, M. W. GPCR biased ligands as novel heart failure therapeutics. Trends Cardiovasc Med 23, 242\u2013249 (2013).","journal-title":"Trends Cardiovasc Med"},{"key":"BFsrep45625_CR33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jcph.111","volume":"53","author":"DG Soergel","year":"2013","unstructured":"Soergel, D. G., Subach, R. A., Cowan, C. L., Violin, J. D. & Lark, M. W. First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol 53, 892\u2013899 (2013).","journal-title":"J Clin Pharmacol"},{"key":"BFsrep45625_CR34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jchf.2014.09.008","volume":"3","author":"GM Felker","year":"2015","unstructured":"Felker, G. M. et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail 3, 193\u2013201 (2015).","journal-title":"JACC Heart Fail"},{"key":"BFsrep45625_CR35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1124\/mol.115.099630","volume":"88","author":"LM Luttrell","year":"2015","unstructured":"Luttrell, L. M., Maudsley, S. & Bohn, L. M. Fulfilling the Promise of \u201cBiased\u201d G Protein-Coupled Receptor Agonism. Mol Pharmacol 88, 579\u2013588 (2015).","journal-title":"Mol Pharmacol"},{"key":"BFsrep45625_CR36","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/00004872-199917121-00001","volume":"17","author":"T Unger","year":"1999","unstructured":"Unger, T. The angiotensin type 2 receptor: variations on an enigmatic theme. Journal of hypertension 17, 1775\u20131786 (1999).","journal-title":"Journal of hypertension"},{"key":"BFsrep45625_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.febslet.2005.11.044","volume":"580","author":"G Turu","year":"2006","unstructured":"Turu, G. et al. Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett 580, 41\u201345 (2006).","journal-title":"FEBS Lett"},{"key":"BFsrep45625_CR38","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","volume":"67","author":"SS Karnik","year":"2015","unstructured":"Karnik, S. S. et al. International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected]. Pharmacol Rev 67, 754\u2013819 (2015).","journal-title":"Pharmacol Rev"},{"key":"BFsrep45625_CR39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/377744a0","volume":"377","author":"L Hein","year":"1995","unstructured":"Hein, L., Barsh, G. S., Pratt, R. E., Dzau, V. J. & Kobilka, B. K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 377, 744\u2013747 (1995).","journal-title":"Nature"},{"key":"BFsrep45625_CR40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.RES.80.2.189","volume":"80","author":"D Henrion","year":"1997","unstructured":"Henrion, D., Benessiano, J. & Levy, B. I. In vitro modulation of a resistance artery diameter by the tissue renin-angiotensin system of a large donor artery. Circ Res 80, 189\u2013195 (1997).","journal-title":"Circ Res"},{"key":"BFsrep45625_CR41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.RES.0000047505.11002.81","volume":"91","author":"L Loufrani","year":"2002","unstructured":"Loufrani, L., Levy, B. I. & Henrion, D. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ Res 91, 1183\u20131189 (2002).","journal-title":"Circ Res"},{"key":"BFsrep45625_CR42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.HYP.0000153792.29478.1d","volume":"45","author":"O Jung","year":"2005","unstructured":"Jung, O. et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45, 759\u2013765 (2005).","journal-title":"Hypertension"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep45625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep45625","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/srep45625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/srep45625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T20:01:23Z","timestamp":1750190483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep45625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,31]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,3]]}},"alternative-id":["BFsrep45625"],"URL":"https:\/\/doi.org\/10.1038\/srep45625","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,31]]},"assertion":[{"value":"6 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45625"}}